Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 14/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.52 |
| ▸ | CDK1 | P06493 | 1/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL173030 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL1032335 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL4312545 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL30515122 | 0.92 | CYP3A4 (0.73) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL97303 | 0.87 | HPRT1 (0.51) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL31069865 | 0.85 | CYP3A4 (0.55) | CYP3A4CYP2D6CDK1CCNB1CCNE1 | |
| SCHEMBL10018164 | 0.85 | CYP3A4 (0.85) | CYP3A4CYP2D6FAP | |
| SCHEMBL14682471 | 0.85 | CYP3A4 (0.85) | CYP3A4CYP2D6FAP | |
| SCHEMBL173053 | 0.84 | CYP2D6 (0.64) | CYP3A4CYP2D6 | |
| SCHEMBL13714851 | 0.84 | CCNE1 (0.47) | CYP3A4CYP2D6CDK1CCNB1CCNE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | CHIMERIX, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-20120058975-A1 | Phosphonate Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-03-08 | — | — | US | disclosed |
| US-8008308-B2 | Phosphonate compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-08-30 | — | — | US | disclosed |
| WO-2011011710-A1 | METHODS OF TREATING VIRAL INFECTIONS | CHIMERIX, INC. (US) | 2011-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072458-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | CYP3A4 2858/4885CYP2D6 3190/4885CDK1 4742/4885 |
| US-20120058975-A1 | Phosphonate Compounds | PHPT1, PHOSPHO1, PIK3CA | CYP3A4 2408/4885CYP2D6 3148/4885CDK1 239/4885 |
| US-20150141375-A1 | Methods of Treating Viral Associated Diseases | HAVCR2, EIF2AK2, TSLP | CYP3A4 2858/4885CYP2D6 3190/4885CDK1 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.